Twenty-eight patients with radiolucent biliary duct stones without cholangitis and jaundice were randomly allocated into two treatment groups receiving ursodeoxycholic acid 12 mg/kg (group A) or placebo (group B) in three daily doses for 24 months. In group A stones disappeared completely in seven patients and partially in one; placebo administration had no effect on stone size and three patien...

OBJECTIVE This study aimed to evaluate gallstone formation, prophylactic and selective cholecystectomy and the effectiveness of ursodeoxycholic acid treatment following laparoscopic Roux-en-Y gastric bypass (LRYGB) in morbid obese patients. MATERIAL AND METHODS Files of 60 patients who underwent LRYGB between October 2006 and March 2011 were retrospectively reviewed. Patients were evaluated f...

Ursodeoxycholic acid (UDCA) makes up a small portion of the naturally occurring bile acid pool in humans, and the drug is effective in several diseases. The mechanism of action involves the displacement of more toxic endogenous bile acids, direct protection of hepatocytes against apoptosis, and stimulation of endogenous secretion of bile to alleviate cholestasis. The use of UDCA has been studie...

conclusions hepatoprotective agents combined with antiviral drugs can significantly improve liver function and liver fibrosis parameters in patients with hepatitis b. results a total of 22 randomized controlled trials encompassing 1,714 cases were considered in the meta-analysis. the obtained results indicated that the combination of antiviral drug and hepatoprotective agent was better than ant...